

In the article "Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer" (Kufel-Grabowska J. *Oncol Clin Pract* 2023; 19: 377–381) in page 380:

text provided

Currently, the DESTINY-Breast09 study is ongoing, with previously untreated patients with advanced HER2-positive breast cancer randomly assigned to 3 arms: docetaxel in combination with pertuzumab and trastuzumab, T-DXd in combination with pertuzumab, and T-DXd.

should be

The DESTINY-Breast09 study, which enrolled patients with advanced HER2-positive previously untreated breast cancer, is currently ongoing.

Online version at: https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/97612 is correct.